DOWDEN NATHAN J (Chief Operating Officer) sold 7.0% of their position (15.01K shares) of ENTRADA THERAPEUTICS, INC. on the open market
Open‑market sale worth $195.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 3/11/2026ACC: 0001873392-26-000002
Officer· Chief Operating Officer
Since Oct 2021
-15.01K
Net shares
Net seller
$195.8K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
15.01K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−3.12K
Price / share
$13.02
Trade value
$40.58K
% of position
1.5%
3/9/2026
213.60K→210.48K
Common Stock
Direct
Shares
−11.89K
Price / share
$13.05
Trade value
$155.19K
% of position
5.7%
3/10/2026
210.48K→198.59K
Total
Net shares
−15.01K
Net value
-$195.77K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/9/2026 | S · Sale | −3.12K | $13.02 | $40.58K | 1.5% | 213.60K | 210.48K |
| Common Stock Direct | 3/10/2026 | S · Sale | −11.89K | $13.05 | $155.19K | 5.7% | 210.48K | 198.59K |
| Total | −15.01K | -$195.77K | ||||||
Derivative Transactions0
No derivative transactions reported